Cyclacel Phar Pr Financials
This page shows Cyclacel Phar Pr (CYCCP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 28 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
FY2025 shows a development-stage business narrowing losses through R&D retrenchment while external financing rebuilds liquidity.
FY2025’s narrower loss reflects spending restraint more than business scale: R&D fell from$19.2M to$848K , which helps explain the lighter cash burn. Financing brought in$5.3M while operations used$4.8M , so the balance-sheet repair was funded externally rather than by a self-funding operating model.
Liquidity looked repaired: the current ratio moved to 4.7x from 0.6x, and positive equity returned. That matters because the company moved away from an immediate balance-sheet squeeze, but the relief came mainly from lower liabilities and fresh capital, not from recurring operating inflows or a broad revenue base.
The asset mix is less purely cash-based than before, which changes how to read liquidity. Inventory of
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Cyclacel Phar Pr's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Cyclacel Phar Pr has an operating margin of -1128.1%, meaning the company retains $-1128 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -27916.3% the prior year.
Cyclacel Phar Pr's revenue surged 1637.2% year-over-year to $747K, reflecting rapid business expansion. This strong growth earns a score of 89/100.
Cyclacel Phar Pr carries a low D/E ratio of 0.20, meaning only $0.20 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 98/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 4.70, Cyclacel Phar Pr holds $4.70 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 94/100.
Cyclacel Phar Pr earns a strong 43.8% return on equity (ROE), meaning it generates $44 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 100/100.
Cyclacel Phar Pr passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Cyclacel Phar Pr generates $-1.59 in operating cash flow (-$4.8M OCF vs $3.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Cyclacel Phar Pr earns $-135.9 in operating income for every $1 of interest expense (-$8.4M vs $62K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Cyclacel Phar Pr generated $747K in revenue in fiscal year 2025. This represents an increase of 1637.2% from the prior year.
Cyclacel Phar Pr's EBITDA was -$8.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 29.8% from the prior year.
Cyclacel Phar Pr reported $3.0M in net income in fiscal year 2025. This represents a decrease of 73.3% from the prior year.
Cyclacel Phar Pr earned $-6.45 per diluted share (EPS) in fiscal year 2025. This represents an increase of 98.7% from the prior year.
Cash & Balance Sheet
Cyclacel Phar Pr held $3.5M in cash against $0 in long-term debt as of fiscal year 2025.
Cyclacel Phar Pr had 5M shares outstanding in fiscal year 2025. This represents an increase of 14529.9% from the prior year.
Margins & Returns
Cyclacel Phar Pr's operating margin was -1128.1% in fiscal year 2025, reflecting core business profitability. This is up 26788.2 percentage points from the prior year.
Cyclacel Phar Pr's net profit margin was 401.3% in fiscal year 2025, showing the share of revenue converted to profit. This is down 25673.1 percentage points from the prior year.
Cyclacel Phar Pr's ROE was 43.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.
Capital Allocation
Cyclacel Phar Pr invested $848K in research and development in fiscal year 2025. This represents a decrease of 87.3% from the prior year.
CYCCP Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $81K | N/A | N/A | $0-100.0% | $10K+150.0% | $4K-86.2% | $29K |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | $5K-92.6% | $68K-91.7% | $822K-6.6% | $880K-7.4% | $950K-53.0% | $2.0M-27.8% | $2.8M |
| SG&A Expenses | N/A | $1.0M-19.6% | $1.2M-70.4% | $4.2M+344.5% | $948K-23.4% | $1.2M-23.9% | $1.6M+2.7% | $1.6M |
| Operating Income | N/A | -$992K+24.7% | -$1.3M+73.8% | -$5.0M-175.5% | -$1.8M+16.0% | -$2.2M+40.3% | -$3.6M+16.3% | -$4.4M |
| Interest Expense | N/A | $9K+350.0% | $2K-66.7% | $6K-80.0% | $30K+275.0% | $8K+128.6% | -$28K-1500.0% | $2K |
| Income Tax | N/A | N/A | $2K | N/A | $1.2M+668.6% | -$210K+49.0% | -$412K+69.6% | -$1.4M |
| Net Income | N/A | -$988K+25.0% | -$1.3M-1527.2% | -$81K-100.4% | $19.4M+1089.9% | -$2.0M+39.9% | -$3.3M-10.6% | -$2.9M |
| EPS (Diluted) | N/A | $-1.31-33.7% | $-0.98 | $0.00 | N/A | $-43.80 | $-172.18-7485.0% | $-2.27 |
CYCCP Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $8.2M+0.3% | $8.2M+85.4% | $4.4M+17.9% | $3.7M-8.8% | $4.1M-23.9% | $5.4M-34.3% | $8.2M+32.8% | $6.2M |
| Current Assets | $6.3M-2.9% | $6.4M+47.0% | $4.4M+18.0% | $3.7M+1.1% | $3.7M-25.2% | $4.9M-36.3% | $7.7M+59.4% | $4.8M |
| Cash & Equivalents | $3.5M-8.7% | $3.8M-10.2% | $4.3M+23.9% | $3.5M+10.0% | $3.1M+5.2% | $3.0M-50.3% | $6.0M+114.4% | $2.8M |
| Inventory | $1.4M+1.2% | $1.4M | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $1.3M+73.4% | $725K | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | $1.6M0.0% | $1.6M | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $1.3M+26.5% | $1.1M+37.9% | $770K+14.6% | $672K-89.3% | $6.3M-1.3% | $6.4M-11.7% | $7.2M-14.1% | $8.4M |
| Current Liabilities | $1.3M+32.9% | $1.0M+31.8% | $760K+14.6% | $663K-89.4% | $6.3M-1.3% | $6.4M-11.6% | $7.2M-13.9% | $8.3M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $6.8M-3.6% | $7.1M+95.4% | $3.6M+18.6% | $3.1M+240.8% | -$2.2M-124.1% | -$970K-197.1% | $999K+145.3% | -$2.2M |
| Retained Earnings | -$454.4M-2.3% | -$444.3M-0.6% | -$441.8M-0.3% | -$440.5M-0.2% | -$439.5M-0.7% | -$436.4M-0.5% | -$434.5M-0.8% | -$431.2M |
CYCCP Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$33K+92.4% | -$434K+58.9% | -$1.1M+67.5% | -$3.2M-139.5% | -$1.4M+55.8% | -$3.1M+0.6% | -$3.1M-538.5% | -$483K |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | $0 | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | -$3.1M | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | $0 | N/A | N/A |
| Financing Cash Flow | -$259K-8533.3% | -$3K-100.2% | $1.9M-48.4% | $3.6M+126.0% | $1.6M+161400.0% | -$1K-100.0% | $6.3M+8060.8% | -$79K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
CYCCP Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | -1224.7% | N/A | N/A | N/A | -21770.0%+69330.0pp | -91100.0%-76082.8pp | -15017.2% |
| Net Margin | N/A | -1219.8% | N/A | N/A | N/A | -19570.0%+61855.0pp | -81425.0%-71266.4pp | -10158.6% |
| Return on Equity | N/A | -13.9%+22.4pp | -36.3%-33.6pp | -2.6% | N/A | N/A | -326.0% | N/A |
| Return on Assets | N/A | -12.1%+17.8pp | -29.9%-27.8pp | -2.2%-475.3pp | 473.2%+509.5pp | -36.4%+3.4pp | -39.8%+8.0pp | -47.8% |
| Current Ratio | 4.70-1.7 | 6.43+0.7 | 5.77+0.2 | 5.60+5.0 | 0.59-0.2 | 0.77-0.3 | 1.07+0.5 | 0.58 |
| Debt-to-Equity | 0.20+0.0 | 0.15-0.1 | 0.210.0 | 0.22+3.1 | -2.88+3.7 | -6.55-13.7 | 7.20+11.0 | -3.79 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | -30670.0% | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Cyclacel Phar Pr's annual revenue?
Cyclacel Phar Pr (CYCCP) reported $747K in total revenue for fiscal year 2025. This represents a 1637.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Cyclacel Phar Pr's revenue growing?
Cyclacel Phar Pr (CYCCP) revenue grew by 1637.2% year-over-year, from $43K to $747K in fiscal year 2025.
Is Cyclacel Phar Pr profitable?
Yes, Cyclacel Phar Pr (CYCCP) reported a net income of $3.0M in fiscal year 2025, with a net profit margin of 401.3%.
What is Cyclacel Phar Pr's EBITDA?
Cyclacel Phar Pr (CYCCP) had EBITDA of -$8.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Cyclacel Phar Pr's operating margin?
Cyclacel Phar Pr (CYCCP) had an operating margin of -1128.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Cyclacel Phar Pr's net profit margin?
Cyclacel Phar Pr (CYCCP) had a net profit margin of 401.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Cyclacel Phar Pr's return on equity (ROE)?
Cyclacel Phar Pr (CYCCP) has a return on equity of 43.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Cyclacel Phar Pr's operating cash flow?
Cyclacel Phar Pr (CYCCP) generated -$4.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Cyclacel Phar Pr's total assets?
Cyclacel Phar Pr (CYCCP) had $8.2M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Cyclacel Phar Pr spend on research and development?
Cyclacel Phar Pr (CYCCP) invested $848K in research and development during fiscal year 2025.
What is Cyclacel Phar Pr's current ratio?
Cyclacel Phar Pr (CYCCP) had a current ratio of 4.70 as of fiscal year 2025, which is generally considered healthy.
What is Cyclacel Phar Pr's debt-to-equity ratio?
Cyclacel Phar Pr (CYCCP) had a debt-to-equity ratio of 0.20 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Cyclacel Phar Pr's return on assets (ROA)?
Cyclacel Phar Pr (CYCCP) had a return on assets of 36.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Cyclacel Phar Pr's cash runway?
Based on fiscal year 2025 data, Cyclacel Phar Pr (CYCCP) had $3.5M in cash against an annual operating cash burn of $4.8M. This gives an estimated cash runway of approximately 9 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Cyclacel Phar Pr's Piotroski F-Score?
Cyclacel Phar Pr (CYCCP) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Cyclacel Phar Pr's earnings high quality?
Cyclacel Phar Pr (CYCCP) has an earnings quality ratio of -1.59x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Cyclacel Phar Pr cover its interest payments?
Cyclacel Phar Pr (CYCCP) has an interest coverage ratio of -135.9x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Cyclacel Phar Pr?
Cyclacel Phar Pr (CYCCP) scores 63 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.